120 related articles for article (PubMed ID: 38720319)
1. Interleukin-21 receptor signaling promotes metabolic dysfunction-associated steatohepatitis-driven hepatocellular carcinoma by inducing immunosuppressive IgA
Xie Y; Huang Y; Li ZY; Jiang W; Shi NX; Lu Y; Cao G; Yin Z; Lin XJ
Mol Cancer; 2024 May; 23(1):95. PubMed ID: 38720319
[TBL] [Abstract][Full Text] [Related]
2. SPTBN1 inhibits inflammatory responses and hepatocarcinogenesis via the stabilization of SOCS1 and downregulation of p65 in hepatocellular carcinoma.
Lin L; Chen S; Wang H; Gao B; Kallakury B; Bhuvaneshwar K; Cahn K; Gusev Y; Wang X; Wu Y; Marshall JL; Zhi X; He AR
Theranostics; 2021; 11(9):4232-4250. PubMed ID: 33754058
[No Abstract] [Full Text] [Related]
3. Apoptosis antagonizing transcription factor-mediated liver damage and inflammation to cancer: Therapeutic intervention by curcumin in experimental metabolic dysfunction associated steatohepatitis-hepatocellular carcinoma.
Srinivas AN; Suresh D; Chidambaram SB; Santhekadur PK; Kumar DP
J Cell Physiol; 2024 Jan; 239(1):135-151. PubMed ID: 37942831
[TBL] [Abstract][Full Text] [Related]
4. Intestinal B cells license metabolic T-cell activation in NASH microbiota/antigen-independently and contribute to fibrosis by IgA-FcR signalling.
Kotsiliti E; Leone V; Schuehle S; Govaere O; Li H; Wolf MJ; Horvatic H; Bierwirth S; Hundertmark J; Inverso D; Zizmare L; Sarusi-Portuguez A; Gupta R; O'Connor T; Giannou AD; Shiri AM; Schlesinger Y; Beccaria MG; Rennert C; Pfister D; Öllinger R; Gadjalova I; Ramadori P; Rahbari M; Rahbari N; Healy ME; Fernández-Vaquero M; Yahoo N; Janzen J; Singh I; Fan C; Liu X; Rau M; Feuchtenberger M; Schwaneck E; Wallace SJ; Cockell S; Wilson-Kanamori J; Ramachandran P; Kho C; Kendall TJ; Leblond AL; Keppler SJ; Bielecki P; Steiger K; Hofmann M; Rippe K; Zitzelsberger H; Weber A; Malek N; Luedde T; Vucur M; Augustin HG; Flavell R; Parnas O; Rad R; Pabst O; Henderson NC; Huber S; Macpherson A; Knolle P; Claassen M; Geier A; Trautwein C; Unger K; Elinav E; Waisman A; Abdullah Z; Haller D; Tacke F; Anstee QM; Heikenwalder M
J Hepatol; 2023 Aug; 79(2):296-313. PubMed ID: 37224925
[TBL] [Abstract][Full Text] [Related]
5. Up-regulation of FGF15/19 signaling promotes hepatocellular carcinoma in the background of fatty liver.
Cui G; Martin RC; Jin H; Liu X; Pandit H; Zhao H; Cai L; Zhang P; Li W; Li Y
J Exp Clin Cancer Res; 2018 Jul; 37(1):136. PubMed ID: 29973237
[TBL] [Abstract][Full Text] [Related]
6. Elevated expression of LCN13 through FXR activation ameliorates hepatocellular lipid accumulation and inflammation.
Qin X; Tan Y; Ren W; Zhou W; Niu R; Liang L; Li J; Cao K; Wei G; Zhu X; Huang M
Int Immunopharmacol; 2024 Apr; 131():111812. PubMed ID: 38493698
[TBL] [Abstract][Full Text] [Related]
7. IL-17 signaling in steatotic hepatocytes and macrophages promotes hepatocellular carcinoma in alcohol-related liver disease.
Ma HY; Yamamoto G; Xu J; Liu X; Karin D; Kim JY; Alexandrov LB; Koyama Y; Nishio T; Benner C; Heinz S; Rosenthal SB; Liang S; Sun M; Karin G; Zhao P; Brodt P; Mckillop IH; Quehenberger O; Dennis E; Saltiel A; Tsukamoto H; Gao B; Karin M; Brenner DA; Kisseleva T
J Hepatol; 2020 May; 72(5):946-959. PubMed ID: 31899206
[TBL] [Abstract][Full Text] [Related]
8. Targeting squalene epoxidase restores anti-PD-1 efficacy in metabolic dysfunction-associated steatohepatitis-induced hepatocellular carcinoma.
Wen J; Zhang X; Wong CC; Zhang Y; Pan Y; Zhou Y; Cheung AH; Liu Y; Ji F; Kang X; Liu D; Yu J
Gut; 2024 May; ():. PubMed ID: 38744443
[TBL] [Abstract][Full Text] [Related]
9. Plasma Cell Polarization to the Immunoglobulin G Phenotype in Hepatocellular Carcinomas Involves Epigenetic Alterations and Promotes Hepatoma Progression in Mice.
Wei Y; Lao XM; Xiao X; Wang XY; Wu ZJ; Zeng QH; Wu CY; Wu RQ; Chen ZX; Zheng L; Li B; Kuang DM
Gastroenterology; 2019 May; 156(6):1890-1904.e16. PubMed ID: 30711627
[TBL] [Abstract][Full Text] [Related]
10. Histidine-rich glycoprotein in metabolic dysfunction-associated steatohepatitis-related disease progression and liver carcinogenesis.
Foglia B; Sutti S; Cannito S; Rosso C; Maggiora M; Casalino A; Bocca C; Novo E; Protopapa F; Ramavath NN; Provera A; Gambella A; Bugianesi E; Tacke F; Albano E; Parola M
Front Immunol; 2024; 15():1342404. PubMed ID: 38469298
[TBL] [Abstract][Full Text] [Related]
11. Tumor-derived exosomal HMGB1 fosters hepatocellular carcinoma immune evasion by promoting TIM-1
Ye L; Zhang Q; Cheng Y; Chen X; Wang G; Shi M; Zhang T; Cao Y; Pan H; Zhang L; Wang G; Deng Y; Yang Y; Chen G
J Immunother Cancer; 2018 Dec; 6(1):145. PubMed ID: 30526680
[TBL] [Abstract][Full Text] [Related]
12. Interleukin-21 receptor gene polymorphism is associated with hepatitis B virus-related hepatocellular carcinoma in Chinese patients.
Liu T; Song J; Zhang M; Li S; Zhang J; Hu X; Zhao Z; Peng W; Wu Q; Bai H; Li Y; Lu X; Ying B
J Clin Lab Anal; 2019 Jun; 33(5):e22860. PubMed ID: 30758075
[TBL] [Abstract][Full Text] [Related]
13. HILPDA promotes NASH-driven HCC development by restraining intracellular fatty acid flux in hypoxia.
Povero D; Chen Y; Johnson SM; McMahon CE; Pan M; Bao H; Petterson XT; Blake E; Lauer KP; O'Brien DR; Yu Y; Graham RP; Taner T; Han X; Razidlo GL; Liu J
J Hepatol; 2023 Aug; 79(2):378-393. PubMed ID: 37061197
[TBL] [Abstract][Full Text] [Related]
14. Interleukin-8 Induces Expression of FOXC1 to Promote Transactivation of CXCR1 and CCL2 in Hepatocellular Carcinoma Cell Lines and Formation of Metastases in Mice.
Huang W; Chen Z; Zhang L; Tian D; Wang D; Fan D; Wu K; Xia L
Gastroenterology; 2015 Oct; 149(4):1053-67.e14. PubMed ID: 26065367
[TBL] [Abstract][Full Text] [Related]
15. NCR
Liu Y; Song Y; Lin D; Lei L; Mei Y; Jin Z; Gong H; Zhu Y; Hu B; Zhang Y; Zhao L; Teo HY; Qiu J; Jiang W; Dong C; Wu D; Huang Y; Liu H
EBioMedicine; 2019 Mar; 41():333-344. PubMed ID: 30827928
[TBL] [Abstract][Full Text] [Related]
16. CTL-Promoting Effects of IL-21 Counteract Murine Lupus in the Parent→F1 Graft-versus-Host Disease Model.
Nguyen V; Rus H; Chen C; Rus V
J Immunol; 2016 Feb; 196(4):1529-40. PubMed ID: 26792801
[TBL] [Abstract][Full Text] [Related]
17. GNAS promotes inflammation-related hepatocellular carcinoma progression by promoting STAT3 activation.
Ding H; Zhang X; Su Y; Jia C; Dai C
Cell Mol Biol Lett; 2020; 25():8. PubMed ID: 32123532
[TBL] [Abstract][Full Text] [Related]
18. OGDHL silencing promotes hepatocellular carcinoma by reprogramming glutamine metabolism.
Dai W; Xu L; Yu X; Zhang G; Guo H; Liu H; Song G; Weng S; Dong L; Zhu J; Liu T; Guo C; Shen X
J Hepatol; 2020 May; 72(5):909-923. PubMed ID: 31899205
[TBL] [Abstract][Full Text] [Related]
19. Blockade of the interleukin-21/interleukin-21 receptor pathway ameliorates disease in animal models of rheumatoid arthritis.
Young DA; Hegen M; Ma HL; Whitters MJ; Albert LM; Lowe L; Senices M; Wu PW; Sibley B; Leathurby Y; Brown TP; Nickerson-Nutter C; Keith JC; Collins M
Arthritis Rheum; 2007 Apr; 56(4):1152-63. PubMed ID: 17393408
[TBL] [Abstract][Full Text] [Related]
20. A novel engineered IL-21 receptor arms T-cell receptor-engineered T cells (TCR-T cells) against hepatocellular carcinoma.
Zhu W; Zhang Z; Chen J; Chen X; Huang L; Zhang X; Huang X; Ma N; Xu W; Yi X; Lu X; Fu X; Li S; Mo G; Wang Y; Yuan G; Zang M; Li Q; Jiang X; He Y; Wu S; He Y; Li Y; Hou J
Signal Transduct Target Ther; 2024 Apr; 9(1):101. PubMed ID: 38643203
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
